COGT
Cogent Biosciences, Inc.
Key Financials
Operating Income
$-333363000
↓ 20.8%
EPS (Diluted)
$-2.16
↓ 11.3%
Net Income
$-328937000
↓ 28.6%
Total Liabilities
$301.2M
↑ 320.7%
Shareholders' Equity
$636.4M
↑ 148.3%
Total Assets
$937.6M
↑ 185.9%
Cash & Equivalents
$312.0M
↑ 217.8%
Operating Cash Flow
$-264444000.00
↓ 27.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 8-K | 6/11/2026 | View on SEC |
| 4 | 5/21/2026 | View on SEC |
| SCHEDULE 13G/A | 5/14/2026 | View on SEC |
| 10-Q | 5/5/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | COGT |
| Company Name | Cogent Biosciences, Inc. |
| CIK | 1622229 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 617-945-5576 |